Oryzon Genomics SA
MAD:ORY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Oryzon Genomics SA
Cash from Financing Activities
Oryzon Genomics SA
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Oryzon Genomics SA
MAD:ORY
|
Cash from Financing Activities
€36.1m
|
CAGR 3-Years
61%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
|
|
Grifols SA
MAD:GRF
|
Cash from Financing Activities
-€529m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-1%
|
|
|
Pharma Mar SA
MAD:PHM
|
Cash from Financing Activities
-€36.5m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
Oryzon Genomics SA
Glance View
Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. The company is headquartered in Cornella De Llobregat, Barcelona and currently employs 44 full-time employees. The company went IPO on 2015-12-10. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The firm also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.
See Also
What is Oryzon Genomics SA's Cash from Financing Activities?
Cash from Financing Activities
36.1m
EUR
Based on the financial report for Dec 31, 2025, Oryzon Genomics SA's Cash from Financing Activities amounts to 36.1m EUR.
What is Oryzon Genomics SA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
9%
Over the last year, the Cash from Financing Activities growth was 426%. The average annual Cash from Financing Activities growth rates for Oryzon Genomics SA have been 61% over the past three years , 14% over the past five years , and 9% over the past ten years .
